American Journal of Cardiovascular Drugs

, Volume 11, Issue 6, pp 383–394

Cardiovascular Disease and Therapeutic Drug-Related Cardiovascular Consequences in HIV-Infected Patients

  • Stacy D. Fisher
  • Brinder S. Kanda
  • Tracie L. Miller
  • Steven E. Lipshultz
Review Article

DOI: 10.2165/11594590-000000000-00000

Cite this article as:
Fisher, S.D., Kanda, B.S., Miller, T.L. et al. Am J Cardiovasc Drugs (2011) 11: 383. doi:10.2165/11594590-000000000-00000

Abstract

The incidence of cardiovascular disease is greatly increased in the HIV-infected population compared with people of the same age without HIV. Cardiovascular manifestations of HIV/AIDS include, but are not limited to, accelerated atherosclerosis, pulmonary arterial hypertension, vasculitis, myocarditis, cardiomyopathy, pericardial diseases, malignancy (myocardial Kaposi sarcoma and B-cell immunoblastic lymphoma), and endocarditis. Drug effects and interactions that challenge the cardiovascular system are even more prevalent in this population, and careful review and surveillance of medication effects is crucial as is careful selection of highly active antiretroviral therapy. A focused assessment and understanding of disease prevalence and presentation is needed as symptoms may be non-specific and cardiovascular physical examination findings indeterminate due to co-morbid conditions in the patient population now living with chronic HIV infection.

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Stacy D. Fisher
    • 1
  • Brinder S. Kanda
    • 2
  • Tracie L. Miller
    • 3
  • Steven E. Lipshultz
    • 3
  1. 1.University of Maryland School of Medicine, University of Maryland Comprehensive Heart CenterBaltimoreUSA
  2. 2.Sinai Hospital of BaltimoreBaltimoreUSA
  3. 3.Division of Pediatric Clinical Research, Department of Pediatrics (D820), and the Batchelor Children’s Research InstituteUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations